All In Biotech

Drug Trial Radar · NCT04840589

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

66

Planned (sponsor's estimate)

Start

Feb 2, 2022

Primary completion

Sep 1, 2028

Study completion Sep 1, 2028

Sponsor

Sponsor type
NIH
First posted
Apr 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ZEN003694 in combination with nivolumab with or without ipilimumab may shrink or stabilize solid tumors.

Conditions

  • Metastatic Malignant Solid Neoplasm
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Refractory Ovarian Carcinoma

Interventions

  • BET Bromodomain Inhibitor ZEN-3694Drug

    Given PO

  • Biopsy ProcedureProcedure

    Undergo a biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo a CT scan

  • IpilimumabBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo a PET scan

  • X-Ray ImagingProcedure

    Undergo x-ray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: Up to 1 cycle of treatment for doublet group (4 weeks) and up to 2 cycles for triplet group (6 weeks)
  2. Phase 2 recommended dose for the combined regimensTime frame: Up to 1 cycle of treatment for doublet group (4 weeks) and up to 2 cycles for triplet group (6 weeks)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

  • Mount Sinai Hospital

    New York, New York

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York

  • Montefiore Medical Center-Weiler Hospital

    The Bronx, New York

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York

  • Case Western Reserve University

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.